Immunocore/$IMCR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
- Ticker
- $IMCR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 524
- Headquarters
- Abingdon, United Kingdom
- Website
- www.immunocore.com
Immunocore Metrics
BasicAdvanced
$1.6B
-
-$0.36
0.74
-
Price and volume
Market cap
$1.6B
Beta
0.74
52-week high
$40.71
52-week low
$27.50
Average daily volume
493K
Financial strength
Current ratio
4.469
Quick ratio
4.148
Long term debt to equity
1.032
Total debt to equity
1.036
Interest coverage (TTM)
-0.23%
Profitability
EBITDA (TTM)
0.756
Gross margin (TTM)
32.87%
Net profit margin (TTM)
-4.20%
Operating margin (TTM)
-0.66%
Effective tax rate (TTM)
-561.57%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-0.16%
Return on equity (TTM)
-4.47%
Valuation
Price to revenue (TTM)
3.587
Price to book
3.74
Price to tangible book (TTM)
3.74
Price to free cash flow (TTM)
-37.552
Free cash flow yield (TTM)
-2.66%
Free cash flow per share (TTM)
-0.812
Growth
Revenue change (TTM)
20.95%
Earnings per share change (TTM)
-13.06%
3-year revenue growth (CAGR)
25.19%
3-year earnings per share growth (CAGR)
-34.44%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Analyst projections of the future price of Immunocore stock.
Bulls say / Bears say
KIMMTRAK sales rose 18% year on year in Q2 2026 and 16% in the first half, with growth in the US and international markets. That gives Immunocore a growing commercial base to fund its plans. (Immunocore)
Five-year trial data showed a 16% survival rate with KIMMTRAK versus 8% in the control arm, with a hazard ratio of 0.67. This longer-term evidence may help support the drug’s use and market position. (Immunocore)
Early brenetafusp results in advanced melanoma showed a 17% response rate and 67% disease control rate at the selected 160 mcg dose. These data support testing the candidate in a Phase 3 trial and could broaden the company’s commercial reach if confirmed. (Immunocore)
KIMMTRAK’s growth is moderating as it reaches high penetration in established markets. US distributor stocking lifted Q2 sales by about $6 million and is expected to weigh on Q3, while underlying sequential growth was about 3%. (StockAnalysis)
KIMMTRAK is Immunocore’s only marketed product and accounts for its sales, leaving the company exposed to any slowdown or competitive pressure on that drug. Management has also said it is preparing for a competitor in uveal melanoma within the next year. (Yahoo Finance, Investing.com)
The company expects significant and rising costs and operating losses as it advances clinical programmes, despite reporting first-half net income in 2026. Its other candidates will not generate revenue unless they complete development and win approval. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Upcoming events
No upcoming events
Immunocore News
AllArticlesVideos
Funds containing Immunocore
Fund name | Fund size | $IMCR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.09% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.